D. Western Therapeutics Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.
The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.
The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.
The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.
Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.